Kura Oncology (KURA) Common Equity (2010 - 2026)

Kura Oncology (KURA) has 17 years of Common Equity data on file, last reported at $107.9 million in Q1 2026.

• On a quarterly basis, Common Equity fell 70.39% year-over-year to $107.9 million in Q1 2026; TTM through Mar 2026 was $107.9 million, a 70.39% decrease from a year earlier, with the FY2025 full-year figure at $174.1 million, down 57.9% from the prior year.
• Common Equity for Q1 2026 stood at $107.9 million, down from $174.1 million in the prior quarter.
• Over the last five years, Common Equity for KURA reached as high as $505.1 million in Q1 2024 and fell as low as $107.9 million in Q1 2026.
• Historically, Common Equity has averaged $379.5 million across 5 years, with a median of $419.6 million in 2022.
• Across the five-year window, Common Equity increased 27.81% in 2024 and slumped 70.39% in 2026, its largest moves.
• Year by year, Common Equity stood at $420.3 million in 2022, then decreased by 5.47% to $397.3 million in 2023, then rose by 4.12% to $413.6 million in 2024, then sank by 57.9% to $174.1 million in 2025, then sank by 38.05% to $107.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $107.9 million in Q1 2026, $174.1 million in Q4 2025, and $242.5 million in Q3 2025.